Biopharma

Human medicines European public assessment report (EPAR): Nyxoid, naloxone, Date of authorisation: 09/11/2017, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 26, 2025 0

Human medicines European public assessment report (EPAR): Nyxoid, naloxone, Date...

Human medicines European public assessment report (EPAR): Cyramza, ramucirumab, Date of authorisation: 19/12/2014, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 26, 2025 0

Human medicines European public assessment report (EPAR): Cyramza, ramucirumab, ...

Cyramza-H-C-2829-P46-0010 : EPAR - Assessment report

Mar 26, 2025 0

Cyramza-H-C-2829-P46-0010 : EPAR - Assessment report

Human medicines European public assessment report (EPAR): Alofisel, darvadstrocel, Date of authorisation: 23/03/2018, Revision: 12, Status: Withdrawn

Human medicines European public assessment report (EPAR...

Mar 26, 2025 0

Human medicines European public assessment report (EPAR): Alofisel, darvadstroce...

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 26, 2025 0

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, ...

Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 26, 2025 0

Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab,...

Human medicines European public assessment report (EPAR): Cosentyx, secukinumab, Date of authorisation: 14/01/2015, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 26, 2025 0

Human medicines European public assessment report (EPAR): Cosentyx, secukinumab,...

Clinical Trials Information System (CTIS): Walk-in clinic - May 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 14 May 2025, 16:00 (CEST) to 14 May 2025, 17:00 (CEST)

Clinical Trials Information System (CTIS): Walk-in clin...

Mar 26, 2025 0

Clinical Trials Information System (CTIS): Walk-in clinic - May 2025, Online, Eu...

MedDRA important medical event terms list - version 28.0

Mar 26, 2025 0

MedDRA important medical event terms list - version 28.0

STAT+: Make America Healthy Again is ringing through statehouses across the U.S.

STAT+: Make America Healthy Again is ringing through st...

Mar 26, 2025 0

With MAHA as an accelerant, states are attempting to exert influence over nation...

Opinion: Dismantling the CDC’s Division of HIV Prevention will cost far more than it saves

Opinion: Dismantling the CDC’s Division of HIV Preventi...

Mar 26, 2025 0

“Taking the CDC out of the fight against HIV would be a huge mistake,” write the...

Opinion: The neurosurgeon keeping ‘Severance’ (relatively) medically accurate

Opinion: The neurosurgeon keeping ‘Severance’ (relative...

Mar 26, 2025 0

How does “Severance,” well, operate? Vijay Agarwal, the neurosurgeon consultant ...

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 26, 2025 0

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Da...

Decision on rules concerning the handling of declared i...

Mar 26, 2025 0

Decision on rules concerning the handling of declared interests of national expe...

Decision of the European Medicines Agency on rules rela...

Mar 26, 2025 0

Decision of the European Medicines Agency on rules relating to Articles 11, 11a ...

MedDRA important medical event terms list - version 28.1

Mar 26, 2025 0

MedDRA important medical event terms list - version 28.1

Palatin’s Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Palatin’s Oral MC4R Agonist PL7737 Receives FDA Orphan ...

Mar 26, 2025 0

CRANBURY, N.J., March 25, 2025 /PRNewswire/ — Palatin Technologies, Inc. (NYSE A...

An ominous shadow falls over mRNA technology

An ominous shadow falls over mRNA technology

Mar 26, 2025 0

Once researchers begin wondering whether their government might pull the rug fro...

The United Laboratories and Novo Nordisk Announce Exclusive License Agreement for UBT251, a GLP-1/GIP/Glucagon Triple Receptor Agonist

The United Laboratories and Novo Nordisk Announce Exclu...

Mar 26, 2025 0

Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories I...

Marty Makary and Jay Bhattacharya confirmed by Senate as FDA commissioner and NIH director

Marty Makary and Jay Bhattacharya confirmed by Senate a...

Mar 26, 2025 0

Marty Makary, at FDA, and Jay Bhattacharya, at NIH, are assuming leadership of a...

Psychological Prehabilitation Boosts Patients' Postsurgical Outcomes

Psychological Prehabilitation Boosts Patients' Postsurg...

Mar 26, 2025 0

TUESDAY, March 25, 2025 -- Psychological prehabilitation may improve four posto...

Stanford professor Jay Bhattacharya confirmed by Senate to run NIH

Stanford professor Jay Bhattacharya confirmed by Senate...

Mar 25, 2025 0

Jay Bhattacharya is aiming to reshape the NIH as the agency faces workforce cuts...

#FierceMadness: Heavyweights face off in Elite Eight round of the 2025 Drug Ad Tournament—VOTE NOW

#FierceMadness: Heavyweights face off in Elite Eight ro...

Mar 25, 2025 0

As the college basketball March Madness tournament gets underway, so too does Fi...

FDA Approves Blujepa (gepotidacin) for the Treatment of Uncomplicated Urinary Tract Infections

FDA Approves Blujepa (gepotidacin) for the Treatment of...

Mar 25, 2025 0

London, UK -- 25 March 2025 -- GSK plc (LSE/NYSE: GSK) today announced that the ...

70
71
72
73
74

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.